Table 1.
Recent publications demonstrating the prevalence of major oncogenes in pediatric PTCs
| PMID | Year | Author | Country | No. of PTCs | Agea | BRAF | RET/PTC | ETV6/NTRK3 | Reference |
|---|---|---|---|---|---|---|---|---|---|
| 32495721 | 2020 | Pekova | Czech | 93 | 14.5 (6–20) | 18 (19.4%) | 19 (20.4%) | 10 (10.8%) | 39 |
| 31456750 | 2019 | Galuppini | Italy | 54 | 14.4 (6.4–17.8) | 8/50 (16.0%) | 14 (25.9%) | 38 | |
| 30924609 | 2019 | Sisdelli | Brazil | 80 | 12.7 (3–18) | 12 (15.0%) | 37 | ||
| 28646474 | 2017 | Geng | China | 48 | (3–13) | 16 (35.4%) | 36 | ||
| 28521635 | 2017 | Hardee | USA | 59 | 24/50 (48.0%) | 35 | |||
| 28209747 | 2017 | Vanden Borre | USA | 12 | 12.8 (7–19) | 2 (16.7%) | 4 (33.3%) | 34 | |
| 28176151 | 2017 | Oishi | Japan | 81 | 17.4 (6–20) | 44 (54.3%) | 33 | ||
| 28077340 | 2017 | Poyrazoğlu | Turkey | 75 | 12.4 (1.3–17.8) | 14/56 (25.0%) | 32 | ||
| 27849443 | 2017 | Cordioli | Brazil | 35 | 11.8 (4–18) | 3 (8.6%) | 14 (40.0%) | 3 (8.6%) | 31 |
| 27824297 | 2017 | Alzahrani | Saudi Atabia | 72 | 15.5b (8–18) | 19 (26.4%) | 30 | ||
| 26951110 | 2016 | Onder | Turkey | 50 | 14.7 (6–18) | 15 (30.0%) | 29 | ||
| 26910217 | 2016 | Gertz | USA | 13 | 13 | 4 (30.8%) | 28 | ||
| 26784937 | 2016 | Prasad | USA | 28 | (6–18) | 13 (46.4%) | 6 (21.4%) | 5 (17.9%) | 27 |
| 26711586 | 2016 | Alzahrani | Saudi Atabia | 53 | 16b (9–18) | 12 (22.6%) | 26 | ||
| 26649796 | 2016 | Nikita | USA | 28 | 14.7 (7.9–18.4) | 9 (32.1%) | 6 (17.6%) | 25 |
aMean (range);
bmedian.